Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Solid Tumor 1Medical Oncology 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Etoposide 156Carboplatin 146Cisplatin 106Topotecan 76durvalumab 52atezolizumab 51Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 25Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × roniciclib × Clear all
NCT01573338 2021-04-08

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Bayer

Phase 1/2 Terminated
43 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02161419 2018-06-25

CONCEPT-SCLC

Bayer

Phase 2 Terminated
142 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡